Current trends in the treatment of primary mediastinal large B-cell lymphoma - An overview

Wspolczesna Onkologia

Volumn 19, Issue 6, 2015, Pages 428-435

  Petković, Ivan ^a  

^a CLINICAL CENTER NIS   (Serbia)

Author keywords

Immunochemotherapy; Primary mediastinal large B cell lymphoma; Radiotherapy; Treatment options

Indexed keywords

ANTINEOPLASTIC AGENT; RITUXIMAB;

CANCER CHEMOTHERAPY; CANCER GENETICS; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER RECURRENCE; CHROMOSOME 9P; CLASSICAL HODGKIN LYMPHOMA; COMPUTER ASSISTED TOMOGRAPHY; GENETIC ANALYSIS; HUMAN; LARGE CELL LYMPHOMA; MEDIASTINUM TUMOR; PERICARDIAL EFFUSION; POSITRON EMISSION TOMOGRAPHY; PRIMARY MEDIASTINAL LARGE B CELL LYMPHOMA; REVIEW; STEM CELL TRANSPLANTATION; SUPERIOR CAVA VEIN SYNDROME; TREATMENT OUTCOME;

EID: 84954328516     PISSN: 14282526     EISSN: None     Source Type: Journal    
DOI: 10.5114/wo.2015.56388     Document Type: Review

References (51)

1. Miller JB, Variakojis D, Bitran JD, Sweet DL, Kinzie JJ, Golomb HM, Ultmann JE. Diffuse histiocytic lymphoma with sclerosis: a clinicopathological entity frequently causing superior vena caval obstruction. Cancer 1982; 47: 748-56.
2. Trump DL, Mann RB. Diffuse large cell and undifferentiated lymphomas with prominent mediastinal involvement: a poor prognostic subset of patients with non-Hodgkin's lymphoma. Cancer 1982; 50: 277-82.
3. Levitt LJ, Aisenberg AC, Harris NL, Linggood RM, Poppema S. Primary non-Hodgkin's lymphoma of the mediastinum. Cancer 1982; 50: 2486-92.
4. Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994; 84: 1361-92.
5. Banks PM, Warnke RA. Mediastinal (thymic) large B-cell lymphoma. In: Jaffe ES, Harris NL, Stein H, et al. (eds.). World Health Organization Classification of Tumours: Pathology and Genetics of Tumors of Hematopoietic and Lymphoid Tissues. IARC Press, Lyon 2001; 175-8.
6. Gaulard P, Harris NL, Pileri SA, et al. Primary mediastinal (thymic) large B-cell lymphoma. In: Swerdlow SH, Campo E, Harris NL, et al. (eds.). World Health Organization Classification of Tumors of haematopietic and lymphoid tissues. IARC Press; Lyon 2008; 250-1.
7. Savage KJ, Monti S, Kutok JL, et al. The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood 2003; 102: 3871-9.
8. Rosenwald A, Wright G, Leroy K, et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med 2003; 198: 851-62.
9. Green MR, Monti S, Rodig SJ, et al. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood 2010; 116: 3268-77.
10. Steidl C, Gascoyne RD. The molecular pathogenesis of primary mediastinal large B-cell lymphoma. Blood 2011; 118: 2659-69.
11. Twa DD, Chan FC, Ben-Neriah S, et al. Genomic rearrangements involving programmed death ligands are recurrent in primary mediastinal large B-cell lymphoma. Blood 2014; 123: 2062-5.
12. Chan WC, Armitage JO, Gascoyne R, et al. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood 1997; 89: 3909-18.
13. Boleti E, Johnson PW. Primary mediastinal B-cell lymphoma. Hematol Oncol 2007; 25: 157-63.
14. Savage KJ, Al-Rajhi N, Voss N, Paltiel C, Klasa R, Gascoyne RD, Connors JM. Favourable outcome of primary mediastinal large B-cell lymphoma in a single institution: the British Columbia experience. Ann Oncol 2006; 17: 123-30.
15. Todeschini G, Ambrosetti A, Meneghini V, et al. Mediastinal large B-cell lymphoma with sclerosis: a clinical study with of 21 patients. J Clin Oncol 1990; 8: 804-8.
16. Hamlin PA, Portlock CS, Straus DJ, et al. Primary mediastinal B-cell lymphoma: optimal therapy and prognostic factor analysis in 141 consecutive patients treated in Memoria Sloan Kettering from 1980 to 1999. Br J Haematol 2005; 130: 691-99.
17. Haioun C, Gaulard P, Roudot-Thoraval F, et al. Mediastinal diffuse large B-cell lymphoma with sclerosis: a condition with a poor prognosis. Am J Clin Oncol 1989; 12: 425-9.
18. Todeschini G, Secchi S, Morra E, et al. Primary mediastinal large B-cell lymphoma (PMLBCL): long-term results from a retrospective multicentre Italian experience in 138 patients treated with CHOP or MACOP-B/VACOP-B. Br J Cancer 2004; 90: 372-6.
19. Bertini M, Orsucci L, Vitolo U, et al. Stage II large B-cell lymphoma with sclerosis treated with MACOP-B. Ann Oncol 1991; 2: 733-7.
20. Lazzarino M, Orlandi E, Paulli M, et al. Primary mediastinal B-cell lymphoma with sclerosis. An aggressive tumor with distinctive clinical and pathologic features. J Clin Oncol 1993; 11: 2306-13.
21. Falini B, Venturi S, Martélli M, et al. Mediastinal large B-cell lymphoma. Clinical and immunohistological findings in 18 patients treated with different third-generation regimens. Br J Haematol 1995; 89: 780-9.
22. Cazals-Hatem D, Lepage E, Brice P, et al. A clinicopathologic study of 141 cases compared with 916 non-mediastinal large B-cell lymphomas, a GELA ("Groupe d'Etude des Lymphomes de l'Adulte") study. Am J Surg Pathol 1996; 20: 877-88.
23. Lazzarino M, Orlandi E, Paulli M, et al. Treatment outcome and prognostic factors for primary mediastinal (Thymic) B-cell lymphoma: a multicenter study of 106 patients. J Clin Oncol 1997; 15: 1646-53.
24. Zinzani PL, Martelli M, Bertini M, et al.; International Extranodal Lymphoma Study Group (IELSG). Induction chemotherapy strategies for primary mediastinal large B-cell lymphoma with sclerosis: a retrospective multinational study on 426 previously untreated patients. Haematologica 2002; 87: 1258-64.
25. Zinzani PL, Stefoni V, Finolezzi E, et al. Rituximab combined with MACOP-B or VACOP-B and radiation therapy in primary mediastinal large B-cell lymphoma: a retrospective study. Clin Lymphoma Myeloma 2009; 9: 381-5.
26. Gutierrez M, Chabner BA, Pearson D, Steinberg SM, Jaffe ES, Cheson BD, Fojo A, Wilson WH. Role of a doxorubicin-containing regimen in relapsed and resistant lymphomas: an 8-year follow-up study of EPOCH. J Clin Oncol 2000; 18: 3633-42.
27. Legha SS, Benjamin RS, Mackay B, et al. Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med 1982; 96: 133-9.
28. Wilson WH, Grossbard ML, Pittaluga S, et al. Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy. Blood 2002; 99: 2685-93.
29. Wilson WH, Bryant G, Bates S, et al. EPOCH chemotherapy: toxicity and efficacy in relapsed and refractory non-Hodgkin's lymphoma. J Clin Oncol 1993; 11: 1573-82.
30. Pfreundschuh M, Trümper L, Osterborg A, et al.; MabThera International Trial Group. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: A randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006; 7: 379-91.
31. Rieger M, Osterborg A, Pettengell R, et al. MabThera International Trial (MInT) Group. Primary mediastinal B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: Results of the MabThera International Trial Group study. Ann Oncol 2011; 22: 664-70.
32. Vassilakopoulos TP, Pangalis GA, Katsigiannis A, et al. Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone with or without radiotherapy in primarymediastinal large B-cell lymphoma: the emerging standard of care. Oncologist 2012; 17: 239-49.
33. Ahn HK, Kim SJ, Yun J, et al. Improved treatment outcome of primary mediastinal large B-cell lymphoma after introduction of rituximab in Korean patients. Int J Hematol 2010; 91: 456-63.
34. Schneider T, Tóth E, Lovey J, et al. Standard CHOP immune-chemotherapy for primary mediastinal lymphomas. Orv Hetil 2011; 152: 735-42.
35. Xu LM, Fang H, Wang WH, et al. Prognostic significance of rituximab and radiotherapy for patients with primary mediastinal large B-cell lymphoma receiving doxorubicin-containing chemotherapy. Leuk Lymphoma 2013; 54: 1684-90.
36. Wang BJ, Cen XN, Qiu ZX, et al. Clinical characteristics and longterm follow-up of 29 patients with primary mediastinal large B cell lymphoma. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2014; 22: 1596-602.
37. Dunleavy K, Pittaluga S, Janik J, et al. The addition of rituximab to dose adjusted (DA)-EPOCH obviates the need for radiation in the treatment of primary mediastinal large B-cell lymphoma (PMBL): A prospective study of 58 patients [Abstract]. Ann Oncol 2008; 19 suppl 4: iv96.
38. Dunleavy K, Pittaluga S, Maeda LS, et al. Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma. N Engl J Med 2013; 368: 1408-16.
39. Purroy N, Bergua J, Gallur L, et al. Long-term follow-up of dose-adjusted EPOCH plus rituximab (DA-EPOCH-R) in untreated patients with poorprognosis large B-cell lymphoma. A phase II study conducted by the Spanish PETHEMA Group. Br J Haematol 2015; 169: 188-98.
40. Avigdor A, Sirotkin T, Kedmi M, et al. The impact of R-VACOP-B and interim FDG-PET/CT on outcome in primary mediastinal large B cell lymphoma. Ann Hematol 2014; 93: 1297-304.
41. Zinzani PL, Broccoli A, Casadei B, et al. The role of rituximab and positron emission tomography in the treatment of primary mediastinal large B-cell lymphoma: experience on 74 patients. Hematol Oncol 2014 Sep 25; doi: 10.1002/hon.2172.
42. Kirk R. Hematological cancer: new standard of care? Nat Rev Clin Oncol 2013; 10: 305.
43. Filippi AR, Piva C, Giunta F, et al. Radiation therapy in primary mediastinal B-cell lymphoma with positron emission tomography positivity after rituximab chemotherapy. Int J Radiat Oncol Biol Phys 2013; 87: 311-6.
44. Martelli M, Ceriani L, Zucca E, et al. [18F]fluorodeoxyglucose positron emission tomography predicts survival after chemoimmunotherapy for primary mediastinal large B-cell lymphoma: results of the International Extranodal Lymphoma Study Group IELSG-26 Study. J Clin Oncol 2014; 32: 1769-75.
45. Rodríguez J, Conde E, Gutiérrez A, et al. Primary mediastinal large cell lymphoma (PMBL): frontline treatment with autologous stem cell transplantation (ASCT). The GEL-TAMO experience. Hematol Oncol 2008; 26: 171-8.
46. Poiré X, van Besien K. Autologous transplant for primary mediastinal B-cell lymphoma. Expert Rev Hematol 2009; 2: 31-6.
47. Stefoni V, Broccoli A, Pellegrini C, Derenzini E, Fina M, Zinzani PL. CNS recurrence of primary mediastinal large B-cell after complete remission. J Neurooncol 2009; 95: 135-9.
48. Hill QA, Owen RG. CNS prophylaxis in lymphoma: who to target and what therapy to use. Blood Rev 2006; 20: 319-32.
49. Hollender A, Kvaloy S, Nome O, Skovlund E, Lote K, Holte H. Central nervous system involvement following diagnosis of non-Hodgkin's lymphoma: a risk model. Ann Oncol 2002; 13: 1099-107.
50. Sasaki M, Sugimoto K. Central nervous system recurrence in the primary mediastinal large B-cell lymphoma: treatment. In: Tumors of the central nervous system. Volume 9 Hayat MA (ed.). Springer; 2012; 21-7.
51. Kuruvilla J, Pintilie M, Tsang R, Nagy T, Keating A, Crump M. Salvage chemotherapy and autologous stem cell transplantation are inferior for relapsed or refractory primary mediastinal large B-cell lymphoma compared with diffuse large B-cell lymphoma. Leuk Lymphoma 2008; 49: 1329-36.